GENOVA Inc. AI Stock Analysis
Want to see JP:9341 full AI Analyst Report?
GENOVA Inc. (9341) AI Stock Analysis
GENOVA Inc.
(TSE/TYO:9341)
The overall score is constrained by a significant deterioration in financial health, specifically collapsing margins and negative free cash flow, which outweigh the strong revenue growth and solid balance sheet. Technical trends are bearish, adding downward pressure. The reasonable P/E and high dividend yield provide some support but are not enough to offset the fundamental operational concerns.
GENOVA Inc. (9341) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 9.97B
- Dividend Yield
- 5.17%
- Average Volume (3M)
- 63.38K
- Price to Earnings (P/E)
- 15.5
- Beta (1Y)
- 0.67
- Revenue Growth
- 46.39%
- EPS Growth
- 12.53%
- Country
- Japan
- Employees
- 529
- Sector
- General
- Sector Strength
- 55
- Industry
- Software - Application
GENOVA Inc. Business Overview & Revenue Model
Company Description
Operating within Japan, GENOVA, Inc. focuses on the digital healthcare market, providing both medical platform services and smart clinic solutions. Its offerings include Medical Doc, a comprehensive online platform that distributes diverse content, s...
GENOVA Inc. Financial Statement Overview
Summary
Financial performance is mixed. Revenue growth is strong (+24%), but profitability has collapsed with net margin falling to 2.4% and operating cash flow turning negative. The solid balance sheet (D/E 0.11) provides some stability, but the severe cash flow deterioration and margin compression are major red flags.
Income Statement
30NegativeBalance Sheet
80PositiveCash Flow
20Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.77B | 11.57B | 10.01B | 8.68B | 6.51B | 4.80B |
| Gross Profit | 6.76B | 6.47B | 7.38B | 6.55B | 4.79B | 3.50B |
| EBITDA | 513.44M | 543.85M | 2.11B | 2.38B | 1.79B | 1.09B |
| Net Income | 623.48M | 275.40M | 1.41B | 1.73B | 1.26B | 686.27M |
Balance Sheet | ||||||
| Total Assets | 11.31B | 10.26B | 8.53B | 8.20B | 5.41B | 2.82B |
| Cash, Cash Equivalents and Short-Term Investments | 5.08B | 5.32B | 5.87B | 5.97B | 3.86B | 1.65B |
| Total Debt | 1.77B | 735.71M | 20.84M | 377.78M | 28.25M | 163.50M |
| Total Liabilities | 5.16B | 3.36B | 1.53B | 2.16B | 1.37B | 1.33B |
| Stockholders Equity | 6.15B | 6.90B | 7.00B | 6.04B | 4.04B | 1.49B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -46.98M | 1.06B | 1.77B | 1.11B | 513.36M |
| Operating Cash Flow | 0 | 53.85M | 1.19B | 1.82B | 1.20B | 623.77M |
| Investing Cash Flow | 0 | -809.75M | -275.93M | -94.24M | -113.45M | -179.06M |
| Financing Cash Flow | 0 | 199.63M | -1.01B | 376.82M | 1.13B | 59.88M |
GENOVA Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9341, the sentiment is Negative. The current price of 575.00 is below the 20-day moving average (MA) of 586.30, below the 50-day MA of 602.56, and below the 200-day MA of 588.93, indicating a bearish trend. The MACD of -8.89 indicates Negative momentum. The RSI at 45.77 is Neutral, neither overbought nor oversold. The STOCH value of 62.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9341.
GENOVA Inc. Peers Comparison
Overall Rating
JP:921867.8Neutral
JP:443854Neutral
JP:448054Neutral
JP:934148Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 68Neutral | JPY 8.05B | 30.81 | ― | 1.31% | 34.18% | -32.29% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | JPY 2.16B | -4.05 | ― | ― | 34.13% | 35.54% | |
| 54Neutral | JPY 63.83B | 36.64 | 11.30% | ― | 21.01% | 10.15% | |
| 48Neutral | JPY 10.35B | 15.53 | ― | 5.17% | 46.39% | 12.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:9341 | GENOVA Inc. | 575.00 | 25.80 | 4.70% | |
| JP:4480 | Medley, Inc. | 1899.00 | -728.00 | -27.71% | |
| JP:4438 | Welby Inc. | 252.00 | -48.00 | -16.00% | |
| JP:9218 | Mental Health Technologies Co. Ltd. | 763.00 | -40.71 | -5.07% | |
| JP:366A | Wellness Communications Corporation | 1083.00 | -122.61 | -10.17% |
GENOVA Inc. Corporate Events
GENOVA Reports Six-Month Results With Sales of ¥7,809 Million
GENOVA Inc. reported consolidated net sales of ¥7,809 million for the six months ended Sept. 30, 2026, up 57.0% year over year. Operating profit was ¥46 million, ordinary profit ¥69 million and profit attributable to owners of the parent ¥358 million...
GENOVA Acquires “Karada ni Iikoto” Healthcare Media Business to Boost Medical Platform
GENOVA Inc. has agreed to acquire the “Karada ni Iikoto” healthcare media business from Central Medience Co., Ltd. for an expected 51 million yen in cash, obtaining contracted editorial services, sponsored content, and PR functions centered on the pl...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
